Edwards Lifesciences Reports PASCAL System For Tricuspid Repair Shows Superiority Compared To Medical Therapy Alone For Six-Month Primary Endpoint Of CLASP II TR Trial
Edwards Lifesciences Corporation (NYSE:EW) today announced that the PASCAL system for tricuspid repair demonstrated superiority compared to medical therapy alone for the six-month primary endpoint of the CLASP II TR
Edwards Lifesciences' PASCAL device helped heart patients more than medicine alone. When a company shows its new medical tool works better, investors watch to see if doctors will use it widely.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.